Alkermes Reschedules Third Quarter 2020 Financial Results Conference Call to 10:30 a.m. ET
Alkermes plc (Nasdaq: ALKS) has rescheduled its third quarter financial results conference call to 10:30 a.m. ET on October 29, 2020, due to technical difficulties with the conference call provider.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alkermes plc (Nasdaq: ALKS) has rescheduled its third quarter financial results conference call to 10:30 a.m. ET on October 29, 2020, due to technical difficulties with the conference call provider. The call will be accessible via a webcast on Alkermes' website. Additionally, a replay will be available until November 5, 2020. Alkermes focuses on developing innovative medicines in neuroscience and oncology, with products targeting addiction and schizophrenia, alongside a promising pipeline for various disorders.
Positive
- The rescheduled conference call allows investors to engage at a clear time, ensuring transparency regarding Q3 results.
Negative
- Technical difficulties delayed the financial results call, potentially causing uncertainty among investors.
Details
News Market Reaction – ALKS
The recorded move for ALKS in the trading session of this news was +5.78%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DUBLIN, Oct. 29, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announces that the conference call to discuss the company's third quarter financial results is rescheduled due to technical difficulties impacting the conference call provider. The company now plans to host the conference call and webcast presentation at 10:30 a.m. ET (2:30 p.m. GMT) on Thursday, Oct. 29, 2020.
The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 844 602 0380 for U.S. callers and +1 862 298 0970 for international callers. The conference ID is 81030951.
A replay of the conference call will be available through Thursday Nov. 5, 2020, and may be accessed by visiting Alkermes' website.
About Alkermes plc
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
Alkermes Contact:
Alex Braun
Investor Relations
+1 781 296 8493
View original content to download multimedia:http://www.prnewswire.com/news-releases/alkermes-reschedules-third-quarter-2020-financial-results-conference-call-to-1030-am-et-301163084.html
SOURCE Alkermes plc
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.